Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value In Health 2022, 25: 1268-1280. PMID: 35490085, PMCID: PMC9045876, DOI: 10.1016/j.jval.2022.03.016.Peer-Reviewed Original ResearchConceptsCohort state-transition modelUS healthcare perspectiveValue of informationFace of uncertaintyQALY willingnessPolicy makersLifetime horizonHealthcare perspectiveState transition modelInformation analysisImmediate approvalModel outcomesImplementation decisionsOptimal momentWillingnessPolicyMakersMost valueCOVID-19DecisionsCostHorizonFurther researchAdditional evidenceUncertaintyPopulation-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53